Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.

Spago Nanomedical AB (publ)

Spago Nanomedical is a Swedish biotechnology company developing nanomaterials for cancer diagnostics and treatment. The company´s two main projects,  SpagoPix and Tumorad, are both based on the same proprietary nanomaterial.SpagoPix is a gadolinium-free contrast agent for magnetic resonance imaging (MRI) with exceptionally high signal strength. By selectively accumulating in tumor tissue via passive tumor targeting, SpagoPix meets a well recognized need for significantly improved soft tissue tumor imaging.Tumorad is a nanoprticle loaded with radionuclides being developed to target soft tissue tumors for radiopharmaceutical treatment. The design of Tumorad  enables it to selectively accumulate in tumor tissue and there deliver a controlled radiation dose.

SE:SPAGONANOMEDICAL